Details for Patent: 8,865,710
✉ Email this page to a colleague
Which drugs does patent 8,865,710 protect, and when does it expire?
Patent 8,865,710 protects VANFLYTA and is included in one NDA.
This patent has seventeen patent family members in sixteen countries.
Drugs Protected by US Patent 8,865,710
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-001 | Jul 20, 2023 | RX | Yes | No | 8,865,710 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-002 | Jul 20, 2023 | RX | Yes | Yes | 8,865,710 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,865,710
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2429524 | ⤷ Subscribe | 301265 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2429524 | ⤷ Subscribe | CA 2024 00013 | Denmark | ⤷ Subscribe |
| European Patent Office | 2429524 | ⤷ Subscribe | PA2024510 | Lithuania | ⤷ Subscribe |
| Australia | 2010248860 | ⤷ Subscribe | |||
| Australia | 2015230806 | ⤷ Subscribe | |||
| Canada | 2761940 | ⤷ Subscribe | |||
| Cyprus | 1122765 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
